

Protalix BioTherapeutics, Inc.  
Form 8-K  
January 31, 2018

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): January 31, 2018**

**Protalix BioTherapeutics, Inc.**

**(Exact name of registrant as specified in its charter)**



Edgar Filing: Protalix BioTherapeutics, Inc. - Form 8-K

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. "

**Item 8.01. Other Events**

On January 31, 2018, the Company issued a press release announcing that the U.S. Food and Drug Administration has granted Fast Track designation to pegunigalsidase alfa, or PRX-102, the Company's plant cell-expressed recombinant, pegylated, cross-linked  $\alpha$ -galactosidase-A candidate for the treatment of Fabry disease. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

**Financial Statements and Exhibits**

**Item 9.01.**

**Exhibits**

(d)

99.1      Press release dated January 31, 2018.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 31, 2018 **PROTALIX  
BIOTHERAPEUTICS, INC.**

By: /s/ Moshe Manor  
Name: Moshe Manor  
Title: President and  
Chief Executive Officer